Skip to main content

Group A Streptococcus vaccine

Award type :
Product Development Award
Product type :
Vaccines
Award year :
2025
Project start date :
11/ 26/ 2025
Project end date :
-
Project duration (months) :
-
Development stage :
Phase 2 (Process optimization for Phase 2)
Target disease :
Group A Streptococcus
Region served :
World
Recipient organization / Country of funding recipient organization :
International Vaccine Institute (IVI) / Republic of Korea
Collaborator(s) / Country :
EuBiologics / Republic of Korea, Australian Strep A Vaccine Initiative (ASAVI) / Australia, GSK Vaccines Institute for Global Health (GVGH) / UK
Funding amount(KRW) :
4,000,000,000

IVI is developing a Group A Streptococcus (GAS) vaccine in collaboration with EuBiologics, ASAVI, and GVGH to address a critical unmet global health need. Although GAS infections cause significant morbidity and mortality, particularly due to Rheumatic Heart Disease, no vaccine currently exists. The vaccine
aims to target multiple pathogenic mechanisms. This project supports technology transfer from GVGH to EuBiologics, leveraging EuBiologics’ GMP manufacturing expertise and WHO prequalification track record. Activities include manufacturing drug substance and drug products for Phase 2 trials, stability testing, and adjuvant down-selection. The vaccine targets infants and young children in low- and middle-income countries and could potentially reduce antibiotic prescriptions by up to 87%, supporting efforts to combat antimicrobial resistance.